双歧杆菌三联活菌胶囊联合莫沙必利对糖尿病胃轻瘫患者血清胃肠激素水平的影响

Effect of Bifid Triple Viable capsules combined with Mosapride on serum gastrointestinal hormone level in patients with diabetic gastroparesis

目的探讨双歧杆菌三联活菌胶囊联合莫沙必利对糖尿病胃轻瘫(DGP)患者血清胃肠激素水平的影响及疗效。方法选择86例DGP患者,随机分为观察组和对照组。两组患者均予调整饮食、适量运动和控制血糖等基础治疗。观察组患者予以双歧杆菌三联活菌胶囊(630 mg/次,2次/d,餐后约30min温水服用)与莫沙必利(5mg/次,3次/d,口服)联合治疗,连用8周。对照组患者单用莫沙必利治疗,其剂量、方法、用法和疗程与观察组相同。观察两组患者治疗前后血清胃肠激素指标[胃动素(MTL)和血管活性肠肽(VIP)]的变化,并评估其临床疗效及不良反应。结果治疗8周后,两组患者血清MTL和血清VIP水平分别较前明显上升或下降(P<0.05或P<0.01),且观察组患者变化幅度较对照组更大(P<0.05);同时观察组患者临床总有效率(95.35%)高于对照组(79.07%)(χ~2=5.11,P<0.05)。观察组与对照组分别出现不良反应4例(9.30%)与6例(13.95%),症状均较轻,两组比较差异无统计学意义(χ~2=0.45,P>0.05)。结论双歧杆菌三联活菌胶囊联合莫沙必利治疗DGP患者疗效确切,安全性较高,作用机制可能与其能调节胃肠激素分泌紊乱,上调血清MTL水平,下调血清VIP水平密切相关。

Objective To discuss the effect of Bifid Triple Viable capsules combined with Mosapride on serum gastrointestinal hormone level in patients with diabetic gastroparesis (DGP).Methods 86patients with DGP were randomly divided into observation group or control group.The patients in two groups were given basic medical treatment including strict diet control,suitable exercise and blood sugar control etc.The observation group was additionally given Bifid Triple Viable capsules (630mg t.i.d orally)and Mosapride (5mg t.i.d)for 8weeks,whde the control group was given Mosapride alone.The changes of serum gastrointestinal hormone [motilin (MTL)and vasoactive intestinal peptide (VIP)]levels of patients in both groups were observed,and the clinical efficacy and drug adverse reactions (DARs)were evaluated.Results After 8weeks treatment,the serum MTL levels were obviously increased in two groups,while the serum VIP levels were obviously declined (P<0.05or P<0.01),and the changes in observation group were much higher than those in control group (P<0.05).Meanwhile,the total clinical efficiency rate in observation group (95.35%)was much higher than that in control group (79.07%)(x^2=5.11,P <0.05). 4(9.30%)and 6cases (13.95%)of DARs with mild symptoms were observed in observation group and control group respectively,with no statistical differences between two groups (x^2=0.45,P>0.05). Conclusion Bifid Triple Viable capsules combined with Mosapride has reliable efficacy in patients with DGP,with satisfactory safety.The mechanism of action may closely relate to its effect of adjusting gastrointestinal hormone disorder,upregulating serum MTL level and downregulating serum VIP level.